



ReadCoor and WAVE Life Sciences Initiate Research Collaboration

June 8, 2017

Collaboration aims to unlock next generation stereopure nucleic acid targets with novel FISSEQ technologies

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 8, 2017-- ReadCoor, Inc., a company reinventing omics and pathology with its panomic spatial sequencing platform, and WAVE Life Sciences Ltd. (NASDAQ:WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced the initiation of a research collaboration to develop a registry of brain cell network maps and advance WAVE's nucleic acid chemistry for targeted delivery to the brain.

Over the next two years, ReadCoor and WAVE have agreed to develop a cell map of the mouse brain and to leverage it to characterize stereopure nucleic acid candidates in specific regions, cell types, and subcellular compartments of the brain. This agreement marks the first major industry collaboration for ReadCoor and increases the number of platform collaborations aimed at unlocking next generation targets for WAVE.

ReadCoor's proprietary FISSEQ (Fluorescent In-Situ Sequencing) platform is designed to provide critical spatial data by combining next generation sequencing and three-dimensional imaging. This unique in-situ sequencing technique is expected to provide meaningful insight of disease state, treatment effects, and outcomes at the molecular level. WAVE's drug development platform is designed to enable the development of stereopure nucleic acid therapeutics, with optimized efficacy, stability, safety, and specificity. By leveraging ReadCoor's technology, WAVE expects to increase its ability to identify transcriptome changes at the regional, cellular, and subcellular levels within the central nervous system and to expand its existing discovery capabilities for next generation candidate development.

Shawn Marcell, CEO of ReadCoor said, "WAVE's unique ability to rationally design nucleic acid therapeutic candidates and ReadCoor's distinctive ability to deliver in-situ spatial data in cells are highly complementary. We are excited to expand the use of FISSEQ in our first industry collaboration with WAVE."

"At WAVE, one of our founding principles is that you cannot truly optimize nucleic acid therapeutics using mixtures of molecules. We believe the same is true when targeting biology using mixtures of cell types," said Paul B. Bolno, M.D., President & CEO of WAVE. "We believe the ReadCoor platform will help enable significantly improved resolution of various neurons, astrocytes and glial cells, thereby assisting WAVE to efficiently select the optimal therapeutic modality for WAVE's next generation of pipeline candidates."

About ReadCoor, Inc.

ReadCoor is leading the next generation of omics by delivering the first panomic spatial sequencing platform to the global audience of researchers, clinicians, pharma and diagnostics companies, and ultimately patients. It is accomplishing this with Fluorescent In-situ Sequencing (FISSEQ), a fundamental new technology, which simultaneously integrates high throughput sequencing, and three-dimensional morphometric analysis. This uniquely powerful platform is expected to revolutionize the next phase in understanding the panomic landscape and may introduce vast new opportunities for important and meaningful clinical insight.

About WAVE Life Sciences

WAVE Life Sciences is a genetic medicines company with an innovative and proprietary synthetic chemistry drug development platform that WAVE is using to design, develop and commercialize a broad pipeline of first-in-class or best-in-class nucleic acid therapeutic candidates for genetically defined diseases. WAVE is initially developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Forward Looking Information

This press release contains forward-looking statements, including statements relating to the distinguishing features of WAVE's drug development platform and of ReadCoor's sequencing technology, and the potential benefits that each party anticipates deriving from the collaboration. These statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will" and similar expressions, and are based on current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, as it relates to WAVE, risks and uncertainties associated with drug development, the regulatory approval process and commercialization, the development and acceptance of therapies with new technologies, as well as other risks and uncertainties that are described in the Risk Factors section of WAVE's most recent annual or quarterly report filed with the U.S. Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and the parties assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20170608005430/en/>

Source: WAVE Life Sciences Ltd.

Media and Investors:

ReadCoor, Inc.
Christine Lafontant, 617-453-2659
christine.lafontant@readcoor.com

or
WAVE Life Sciences
Jillian Connell, 617-949-2981
jconnell@wavelifesci.com